DBV Technologies announces the appointment of the new Chairman of its Audit Committee and of Danièle Guyot-Caparros to the Board of Directors – 2022-10-03 at 22:30

Montrouge, France, October 3 (10:30 p.m. CEST) 2022

DBV Technologies announces the appointment of the new

P

resident of his

VS

omitted from

HAS

udit and Danièle Guyot-Caparros at

VS

advice of

HAS

administration

DBV Technologies (Euronext: DBV; ISIN: FR0010417345; Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Mr. Timothy E. Morris, independent director member of the Audit Committee and Administration (the “Board”) of DBV, was appointed Chairman of the Audit Committee to replace Ms. Viviane Monges who is leaving the Board as of October 3, 2022. DBV also announced the appointment of Ms. Danièle Guyot-Caparros by DBV’s Board of Directors as an independent director to fill the vacant position of Ms. Monges as of October 3, 2022. Following these changes, the Board remains composed of ten members.

Mr. Morris has been a member of the Board of Directors and the Audit Committee of DBV Technologies since April 2021. Mr. Morris has served as Chief Operating Officer and Chief Financial Officer of Humanigen, Inc. since August 2020. He currently serves on the Boards of Humanigen Australia Pty Ltd, Humanigen Ltd (UK) and Humanigen Europe Ltd, all wholly owned subsidiaries of Humanigen, Inc. Mr. Morris has 38 years of professional experience in finance and accounting, including 25 years as CFO of listed biotechnology companies.

Ms. Monges has been a member of the company’s Board of Directors and Audit Committee since May 2019 and Chair of the Audit Committee of the Board of Directors since March 2021.



We are delighted to welcome Tim Morris to his new role as

P

resident of

VS

omitted from

HAS

udi

you

said Michel de Rosen, Chairman of the Board. ”

Tim’s financial background has served DBV Technologies well since joining the

VS

advice of

HAS

administration

and I am certain that his demonstrated expertise and experience

,

will be useful to him in his new role. On behalf of

VS

advice of

HAS

administration, the DBV management team and our shareholders, I thank Viviane for her efforts and her commitment to society. We appreciate

a lot

the leadership and insight that Viviane demonstrated in

within our

VS

advice of

HAS

administration

and

from

VS

omitted from

HAS

udit and wish him good luck in his new projects. »

“I have enjoyed the time spent as a member of the

VS

advice of

HAS

administration of DBV Technologies and

P

resident of his

VS

omitted from

HAS

audit. I have confidence in the Viaskin technology that DBV is developing and I am convinced that it will one day be able to bring a benefit

significant

to patients if approved.

I wish

all

my wishes of success

to DBV and to

m

are

Council colleagues

he

declared Ms. Viviane Monges.

The Board of DBV Technologies has finalized the provisional appointment of a new independent director to fill the position left vacant by Ms. Monges within the Audit Committee and the Board. Ms. Danièle Guyot-Caparros joins the Board as a new independent director, subject to ratification by shareholders at the next DBV annual shareholders’ meeting, and as a member of the Audit Committee. Ms. Guyot-Caparros has extensive experience in finance and commercial operations. She began her career in auditing and corporate finance at PricewaterhouseCoopers (PWC) before joining Rhône-Poulenc-Rorer (later Aventis and Sanofi), where she held several Financial Management positions, including those of Director World Financial Officer for Research and Development and Financial Director of Group Planning in Europe. Ms. Guyot-Caparros has also assumed responsibilities in business development, pricing and portfolio management. In 2008, Ms. Guyot-Caparros became a senior advisor for Deloitte France where she supported the development of the life sciences and healthcare sector.



I am delighted to join the

VS

advice of

HAS

administration of DBV Technologies at an important moment in the company’s regulatory journey

“, explained Ms. Guyot-Caparros. ”

I welcome the publication of the results of the EPITOPE study of DBV in children aged 1 to 3 years with peanut allergy and I will be delighted to support the progress of the

company in the pivotal phase 3 VITESSE study in children aged 4 to 7 years with peanut allergy. These age groups are determinants of the disease and families have been waiting for new treatment options for a long time. I am eager to

participate in monitoring

e

t supervision

of the financial management of DBV

“.

In addition to her business experience, Ms. Guyot-Caparros has held positions on the boards of directors of biotechnology and medical technology companies. She sat on the Board of Directors and the Audit Committee of Diaxonhit (now Eurobio Scientific), a company listed on Euronext Growth. Ms. Guyot-Caparros was Chairman of the Audit Committee of Supersonic Imagine from July 2018 to September 2019 until its acquisition. From 2013 to 2022, she chaired the ONXEO Audit Committee and was also Chairwoman of the ONXEO Board of Directors from May 2019 to July 2021.



We welcome Danièle Guyot-Caparros as a new director to the DBV Board of Directors

said Michel de Rosen, Chairman of the Board. ”

Danièle has a wealth of experience in senior financial positions in

various companies in the chemical, pharmaceutical and medical technology sectors. She has

already seated

on Boards of Directors and Audit Committees where she has demonstrated strong leadership that will add to the leadership of DBV’s Board of Directors. Danièle’s appointment is part of the transformation of our Board of Directors, as we continue to ensure that we have the right mix of skills and experience.

s

to achieve our strategic and financial objectives. »

The provisional appointment of Ms. Danièle Guyot-Caparros will be submitted to the vote of the shareholders at the Ordinary and Extraordinary General Meeting of 2023. The company will later communicate the details and procedures relating to the Ordinary and Extraordinary General Meeting of DBV Technologies in 2023 .

About DBV Technologies


DBV Technologies is developing Viaskin™, an experimental proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on Epicutaneous Immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company aims to safely transform the treatment of patients with food allergies. DBV Technologies’ food allergy programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies’ global headquarters are located in Montrouge, France, and its North American operations are based in Basking Ridge, NJ. The Company’s ordinary shares are traded on the B segment of Euronext Paris (symbol: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing half an ordinary share) are traded on the Nasdaq Global Select Market ( symbol: DBVT).

Forward-looking statements


This press release may contain forward-looking statements and estimates, including statements regarding DBV Technologies’ regulatory process and DBV Technologies’ pipeline potential. These forward-looking statements and estimates do not constitute promises or guarantees and involve significant risks and uncertainties and may be impacted by market conditions as well as other risks and uncertainties set forth in DBV Technologies’ regulatory filings with the Autorité des marchés financiers (“AMF”), DBV Technologies’ filings and reports with the US Securities and Exchange Commission (“SEC”), and future filings and reports with the AMF. Current and potential investors are cautioned not to place undue reliance on such forward-looking statements and estimates, which speak only as of the date hereof. Except as required by applicable law, DBV Technologies does not undertake to update or revise the information contained in this press release.

Investor contacts


Anne Pollack

DBV Technologies

+1 857-529-2363

[email protected]

Media contacts


Angela Marcucci

DBV Technologies

+1 646-842-2393

[email protected]

Viaskin and EPIT are registered trademarks of DBV Technologies.

Attachment

.

Leave a Comment